BS_ERWT0ZWE
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 6.879
- sex
- M
- new_clusters
- C5
- umap1_2d
- 4.623532078
- umap2_2d
- 5.949680265
- umap1_3d
- 2.707883542
- umap2_3d
- -0.576009211
- umap3_3d
- -3.668231726
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.140
- MYOGENESIS+0.100
- PEROXISOME+0.080
- HEME_METABOLISM+0.060
- NOTCH_SIGNALING+0.060
- PANCREAS_BETA_CELLS+0.060
- OXIDATIVE_PHOSPHORYLATION+0.020
- PROTEIN_SECRETION+0.020
- XENOBIOTIC_METABOLISM+0.020
- P53_PATHWAY+0.010
Top 10 suppressed
- MYC_TARGETS_V2-0.590
- E2F_TARGETS-0.490
- G2M_CHECKPOINT-0.440
- MYC_TARGETS_V1-0.390
- ANGIOGENESIS-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- MTORC1_SIGNALING-0.320
- ALLOGRAFT_REJECTION-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
- INFLAMMATORY_RESPONSE-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0810 | Med | Medulloblastoma | 0.899 |
| 2 | SRR975556 | — | — | 0.876 |
| 3 | MDT-AP-0153 | Med | Medulloblastoma | 0.869 |
| 4 | SRR975563 | — | — | 0.867 |
| 5 | BS_T2QPMZCM | low-grade glioma | — | 0.865 |
| 6 | BS_G9XE3N9T | pilocytic astrocytoma | — | 0.865 |
| 7 | MDT-AP-0009 | Med | Medulloblastoma | 0.854 |
| 8 | C3N-02950 | — | cohortA1 | 0.852 |
| 9 | C3L-02958 | — | cohortA1 | 0.847 |
| 10 | MDT-AP-0734 | Med | Medulloblastoma | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.020 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.020 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |